Key Takeaways
- Modest quarter, ambitious setup: Sales grew 13.6% YoY and EBITDA rose 25% YoY, but the quarter was held back by erratic monsoons, delayed rabi sowing, and export headwinds. Management expects a sharp Q4 recovery and has guided for 25% growth in FY24.
- Product focus is working: The "Maharatna" product strategy is concentrating growth: Shinwa and Hachiman alone added ~INR 100 crores in turnover YoY, while Torry and Izuki contributed another ~INR 60 crores.
- Export hit is temporary, recovery promised: Exports will close FY23 at INR 110–115 crores, a ~30% miss versus the INR 150 crore target, due to dollar shortages and currency depreciation in key markets. Management assures a rebound to INR 200 crores plus in FY24.
- Margin story is about mix, not just cost: Muted margins this quarter reflected inventory mark-to-market hits from volatile raw material prices, but the structural driver is a shift toward higher-margin Maharatna products (35%+ gross margin) and away from low-margin generics (~10% gross margin).
- What to watch next quarter: Whether the four March product launches (Mission, Tornado, Bouncer, Supremo SP) actually deliver the promised Q4 wake-up, the pace of export order normalization, and any concrete progress on the Dahej backward integration project.
Product Strategy & Portfolio Shift
- Maharatna concentration: Focused Maharatna and Maharatna products together now contribute more than 555% of business, with Shinwa expected to be the largest product in FY23 and set to multiply next year alongside Torry and Hachiman.
- New launch momentum: Four products are launching in March itself: Bouncer (glyphosate-potassium salt, a new formulation for India), Supremo SP (first-time manufacture in India), Tornado (a mixture of two formulations), and Mission (CTPR, the country's largest-selling insecticide).
- CTPR ambition: The company obtained CTPR registration ~6 months back but delayed launch while deciding to manufacture the technical in-house; management now targets a big number from it and lists it among the top 6 products.
- Product rationalization underway: More than 40 formulations or brands are being removed from the range, with a target to cut ~40 more this year; the goal is to reduce low-margin product revenue share to 35% next fiscal and 25% over 2–3 years.
- Revenue trajectory by vintage: Products launched in FY19 show flat or declining revenue; FY20 products went from INR 30 crores to INR 47 crores, with last year at INR 55 crores; the major increase comes only from FY21, FY22, and FY23 launches, confirming the portfolio's reliance on fresh introductions.
Rajesh Aggarwal: "But our stance is that we provide the company's solution to the farmers, so we are working regularly to provide the new generation solutions."
Export: The Miss and the Recovery Bet
- FY23 export shortfall: Exports are expected to close around INR 110–115 crores, a hit of about 30% versus the INR 150 crore target, driven by dollar shortages in Africa, the Middle East, and Latin America that prevented banks from opening LCs even after advance payments.
- FY24 export target: Management expects exports to cross INR 200 crores plus next year, citing product registrations in new markets, technical restrictions in advanced markets (Europe, Americas) that create opportunity, and emerging CRAMS opportunities.
- Geographic diversification: The company is investing in registrations across Europe, Brazil, NAFTA countries, Latin America, and Canada, moving beyond its traditional Africa and Middle East base.
- Backward integration as export enabler: At Dahej, the company is backward-integrating for two technicals by making intermediates, which is intended to strengthen its competitive position in international markets.
Rajesh Aggarwal: "But I can assure you that next year, we should cross INR 200 crores plus in the international market because of various reasons actually, not only the registrations of some of the products which we are getting into these markets."
Margin Dynamics
- Q3 margin pressure: Muted margins this quarter came from a big impact of market price fluctuations: raw material prices were very high initially, then became modest, while international market volatility, currency swings, and crude fluctuations forced inventory mark-to-market adjustments.
- M2M losses are non-cash: Management emphasized that the mark-to-market adjustment has already been taken in the balance sheet, these are not real losses, and they create opportunity for future gains when inventory is sold.
- Structural margin driver: Focused Maharatna products carry 35%+ gross margins, while generic products operate below 10%; the ongoing portfolio shift toward the former is the core margin expansion story.
- B2B vs B2C margin parity: At the EBITDA level, B2B and B2C margins are more or less similar because new-generation molecules carry better margins than older generic products across both channels.
- Raw material tailwind: Last year, the company was forced to purchase raw materials at very high prices during December–February; this year, post-Diwali purchases were made at aggressive, lower prices, which will help margins going forward.
- Forex impact: The company took a currency hit of INR 13–14 crores for the year and is already hedged in the market.
Rajesh Aggarwal: "That adjustment has already happened in the balance sheet, and it gives the opportunity for making money in the future, yes, because it is all M2M losses, they are not real losses."
Capex & Capacity Build-Out
- Dahej project nearing completion: All running capital expenses and projects, including the Dahej facility, are expected to be completed by March 2023; 1 megawatt of solar panels has been installed, and solid fuel boilers are being introduced to replace gas at roughly half or less than half the cost.
- New Rajasthan site: A large site of more than 15 acres has been acquired, with possession expected in March; Phase 1 (formulations and some biological activities) will start very soon on an already-constructed site, while Phase 2 (a technical synthesis plant, a 2-year project) begins in the latter half of 2023.
- IIL Biologicals expansion: An R&D center and plant for IIL Biologicals will be built at the new Rajasthan site, with 3 or 4 product launches expected in the biological segment.
- Capacity doubling at Chopanki: The company has already doubled capacity for manufacturing technicals at its Chopanki plant.
- Backward integration scope: The company expects to achieve 100% captive usage of backward-integrated products for some molecules, while selling some quantities into the market; total imports from China are not expected to decline because new volume introductions still require imports.
Demand Environment & Seasonality
- Kharif disruption: Erratic monsoons caused excessive rainfall in some areas, deficits in many, and delayed crop sowings: rice was impacted by 4%, pulses by 6%, oilseeds by 2%, while coarse cereals and soybeans increased by 5% and 6% respectively; pest infestation added further issues.
- Rabi recovery: The rabi season showed good recovery, particularly in the southern part of the country, due to good rains leading to strong water levels in reservoirs and wet soils.
- Geographic skew in Q3: More than 50% of B2C and brand segment sales came from the South region, with East, West, and North contributing the other 50%, reflecting the regional concentration of rabi recovery.
- Inventory rebuild underway: Management noted that the inventory rebuild process is on and expects a good season and a good start to the new year because of the many new molecules being introduced.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue growth | 25% growth | FY24 |
| Medium-term growth trajectory | Continue growing by 25% for next 2–3 years | FY24–FY26 |
| FY24 export revenue | Cross INR 200 crores plus | FY24 |
| B2B segment jump | ~INR 200 crores increase | FY24 |
| B2C segment jump | ~INR 200 crores increase | FY24 |
| Low-margin product revenue share | Bring down to 35% | Next fiscal (FY24) |
| Low-margin product revenue share | Bring down to 30% | Over 2–3 years |
| Dahej project completion | All running capex/projects completed | March 2023 |
| New Rajasthan Phase 2 start | Technical synthesis plant construction begins | Latter half of 2023 |
| Margin growth vs revenue growth | If revenue grows 20%, margins will grow better than that, evident from Q1 itself | Q1 FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹356 cr, +13.6% YoY |
| EBITDA | ₹23.2 cr, +25% YoY |
| EBITDA margin | +60 bps YoY |
| 9M revenue | ~₹1,500 cr |
| 9M EBITDA | ~₹150 cr, +107 bps YoY margin |
| 9M Maharatna contribution | ₹596 cr, ~55% of total revenue |
| 9M product mix | Insecticides 44%, Herbicides 41.6%, Fungicides 10% |
| Q3 product mix | Fungicides 8% |
| FY23 export target revised | ₹110–115 cr, down ~30% from original ₹150 cr target |
| FY24 export target | ₹200 cr+ |
| FY24 revenue growth target | 25% |
| FY24 B2B growth target | ₹200 cr jump |
| FY24 B2C growth target | ₹200 cr jump |
| Market share | 4–5% |
| Forex loss (full year) | ₹14 cr |
| Revenue from products with <10% gross margin | ~40–45% of total |
| Dahej project cost | up by ₹160 cr from planned ₹1,110 cr budget |